Prognosis and Treatment Outcomes of Gastric Cancer Patients with Hepatic Metastasis.
10.5230/jkgca.2006.6.4.237
- Author:
Eun Mi KIM
1
;
Se Won KIM
;
Sang Woon KIM
;
Sun Kyo SONG
;
Kyung Hee LEE
;
Myung Soo HYUN
;
Won Kyu PARK
;
Jae Chun CHANG
Author Information
1. Department of Surgery, Yeungnam Medical Center, Yeungnam University, Daegu, Korea. sksong@med.yu.ac.kr
- Publication Type:Original Article
- Keywords:
Prognosis;
Synchronous;
Metachronous;
Hepatic metastasis;
Gastric cancer
- MeSH:
Drug Therapy;
Gastrectomy;
Humans;
Medical Records;
Multivariate Analysis;
Neoplasm Metastasis*;
Prevalence;
Prognosis*;
Retrospective Studies;
Stomach Neoplasms*;
Surgical Procedures, Operative;
Survival Rate
- From:Journal of the Korean Gastric Cancer Association
2006;6(4):237-243
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was conducted to evaluate the treatment outcomes and the prognosis for gastric cancer patients with hepatic metastasis. MATERIALS AND METHODS: This retrospective study was based on the medical records of 85 gastric cancer patients with hepatic metastasis (62 synchronous and, 23 metachronous) who received chemotherapy with or without resectional therapy from March 1990 to March 2006. The survival rate was analyzed according to clinicopathologic factors and therapeutic factors, such as whether or not a gastrectomy, a hepatic resection, and/or chemotherapy had been performed. RESULTS: The median survival of gastric cancer patients with hepatic metastasis was 11 months (synchronous: 11 months and metachronous: 17 months). The rates of gastrectomies and hepatic resections in the synchronous group were 24.1% and 16.1%, respectively. A 23.5% prevalence of extra-hepatic metastasis was observed. The median survivals of patients who underwent a gastrectomy with a hepatic resection, a gastrectomy alone, and non-surgical treatment were 60, 18, and 9 months, respectively (P<0.05). The disease-free median survival of the metachronous group was 8 (3~39) months. There was no difference in initial pathologic stage and frequency of hepatic metastasis after the gastrectomy in the metachronous group. In the synchronous group, extra-hepatic metastasis, a gastrectomy as the operative procedure, a hepatic resection as the operative procedure and the response to chemotherapy were statistically significant in the univariate analysis, and a hepatic resection as the operative procedure, the response to chemotherapy, and extra-hepatic metastasis were independant prognostic factors identified by the multivariate analysis. In the metachronous group, extra-hepatic metastasis, the response to chemotherapy and differentiation were statistically significant in the univariate analysis, and extra-hepatic metastasis was an independent prognostic factor identified by the multivariate analysis. CONCLUSION: An aggressive surgical therapy and effective chemotherapy are necessary in the treatment of gastric cancer patients with hepatic metastasis.
